Abstract
Background: Total serum IgE (tIgE) is an important intermediate phenotype of allergic disease. Whole genome genetic association studies across ancestries may identify important determinants of IgE. Objective: We aimed to increase understanding of genetic variants affecting tIgE production across the ancestry and allergic disease spectrum by leveraging data from the National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine program; the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA); and the Atopic Dermatitis Research Network (N = 21,901). Methods: We performed genome-wide association within strata of study, disease, and ancestry groups, and we combined results via a meta-regression approach that models heterogeneity attributable to ancestry. We also tested for association between HLA alleles called from whole genome sequence data and tIgE, assessing replication of associations in HLA alleles called from genotype array data. Results: We identified 6 loci at genome-wide significance (P < 5 × 10–9), including 4 loci previously reported as genome-wide significant for tIgE, as well as new regions in chr11q13.5 and chr15q22.2, which were also identified in prior genome-wide association studies of atopic dermatitis and asthma. In the HLA allele association study, HLA-A∗02:01 was associated with decreased tIgE level (Pdiscovery = 2 × 10–4; Preplication = 5 × 10–4; Pdiscovery+replication = 4 × 10–7), and HLA-DQB1∗03:02 was strongly associated with decreased tIgE level in Hispanic/Latino ancestry populations (PHispanic/Latino discovery+replication = 8 × 10–8). Conclusion: We performed the largest genome-wide association study and HLA association study of tIgE focused on ancestrally diverse populations and found several known tIgE and allergic disease loci that are relevant in non-European ancestry populations.
Original language | English (US) |
---|---|
Pages (from-to) | 1589-1595 |
Number of pages | 7 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 148 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2021 |
Externally published | Yes |
Keywords
- Total serum IgE
- asthma
- atopic dermatitis
- genome-wide association study
- human leukocyte antigen
- multiethnic
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Multiethnic genome-wide and HLA association study of total serum IgE level'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology, Vol. 148, No. 6, 12.2021, p. 1589-1595.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Multiethnic genome-wide and HLA association study of total serum IgE level
AU - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
AU - Daya, Michelle
AU - Cox, Corey
AU - Acevedo, Nathalie
AU - Boorgula, Meher P.
AU - Campbell, Monica
AU - Chavan, Sameer
AU - Cho, Michael H.
AU - David, Gloria L.
AU - Kachroo, Priyadarshini
AU - Lasky-Su, Jessica
AU - Li, Xingnan
AU - McHugh, Caitlin P.
AU - Qiao, Dandi
AU - Rafaels, Nicholas
AU - Beck, Lisa A.
AU - Bleecker, Eugene R.
AU - Caraballo, Luis
AU - Cupples, Adrienne L.
AU - Figueiredo, Camila A.
AU - Gallo, Richard L.
AU - Hanifin, Jon
AU - Hansel, Nadia N.
AU - Hata, Tissa R.
AU - Hersh, Craig P.
AU - Knight-Madden, Jennifer
AU - Leung, Donald Y.M.
AU - Guttman-Yassky, Emma
AU - Meyers, Deborah A.
AU - O'Connor, George
AU - Ober, Carole
AU - Ong, Peck Y.
AU - Ortega, Victor E.
AU - Paller, Amy S.
AU - Putcha, Nirupama
AU - Reed, Robert M.
AU - Schneider, Lynda C.
AU - Silverman, Edwin K.
AU - Slifka, Mark K.
AU - Spergel, Jonathan M.
AU - Vasan, Ramachandran S.
AU - Viaud-Martinez, Karine A.
AU - Watson, Harold
AU - Weiss, Scott T.
AU - Ruczinski, Ingo
AU - Beaty, Terri H.
AU - Mathias, Rasika A.
AU - Barnes, Kathleen C.
N1 - Funding Information: Supported by the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) through the BioData Catalyst program (awards 1OT3HL142479-01, 1OT3HL142478-01, 1OT3HL142481-01, 1OT3HL142480-01, and 1OT3HL147154), as well as by NHLBI grant 1R01HL104608-01A14 and NIH/National Institute of Allergy and Infectious Diseases grant U19 AI117673. C.P.H. reports grants from the NHLBI and the Alpha-1 Foundation. Funding for the Barbados Asthma Genetics Study was provided by NIH grants R01HL104608, R01HL087699, and HL104608 S1. Funding Information: Supported by the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) through the BioData Catalyst program (awards 1OT3HL142479-01, 1OT3HL142478-01, 1OT3HL142481-01, 1OT3HL142480-01, and 1OT3HL147154), as well as by NHLBI grant 1R01HL104608-01A14 and NIH/National Institute of Allergy and Infectious Diseases grant U19 AI117673. C.P.H. reports grants from the NHLBI and the Alpha-1 Foundation. Funding for the Barbados Asthma Genetics Study was provided by NIH grants R01HL104608, R01HL087699, and HL104608 S1.Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program were supported by the National Heart, Lung, and Blood Institute (NHLBI). Genome sequencing for NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish study (phs000956.v4.p1) was performed at Broad Genomics (the genomics platform of the Broad Institute of Harvard and MIT, 3R01HL121007-01S1). Genome sequencing for NHLBI TOPMed: The Genetics and Epidemiology of Asthma in Barbados study (phs001143.v3.p1) was performed at Illumina (3R01HL104608-04S1). We gratefully acknowledge the contributions of Pissamai and Trevor Maul, Paul Levett, Anselm Hennis, P. Michele Lashley, Raana Naidu, Malcolm Howitt, and Timothy Roach, as well as the numerous health care providers and community clinics and coinvestigators who assisted in the phenotyping and collection of DNA samples and the families and patients for generously donating DNA samples to the Barbados Asthma Genetics Study, funding, for which was provided by National Institutes of Health (NIH) (grants R01HL104608, R01HL087699, and HL104608 S1). Genome sequencing for the NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene) project (phs000951.v4.p4) was performed at Broad Genomics (HHSN268201500014C). Genome sequencing for the NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica study (phs000988.v4.p1) was performed at the Northwest Genomics Center (3R37HL066289-13S1). Measurement of IgE levels in the CRA study was supported by R37 HL066289 and P01HL132825. Genome sequencing for the NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study (phs000974.v4.p3) was performed at Broad Genomics (3U54HG003067-12S2). Genome sequencing for the NHLBI TOPMed: Severe Asthma Research Program (phs001446.v1.p1) was performed at New York Genomic Center Genomics (HHSN268201500016C). Core support, including centralized genomic read mapping and genotype calling along with variant quality metrics and filtering, was provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support, including phenotype harmonization, data management, sample-identity quality control, and general program coordination, was provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). The TOPMed component of the Amish Research Program was supported by NIH grants R01 HL121007, U01 HL072515, and R01 AG18728 (e-mail Rhea Cosentino [rcosenti@som.umaryland.edu] for additional input). The COPDGene project was supported by the NHLBI (awards U01 HL089897 and U01 HL089856). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHLBI or the NIH. The COPDGene project is also supported by the Chronic Obstructive Pulmonary Disease Foundation through contributions made to an industry advisory board comprising of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. A full listing of COPDGene investigators can be found at: http://www.copdgene.org/directory. Measurement of IgE levels in COPDGene was supported by R01HL130512 and a grant from Novartis. The Framingham Heart Study acknowledges support from the NHLBI (contracts NO1-HC-25195, HHSN268201500001I, and 75N92019D00031 and grant supplement R01 HL092577-06S1) for this research. We also acknowledge the dedication of the Framingham Heart Study participants, without whom this research would not have been possible. We gratefully acknowledge the studies and participants who provided biologic samples and data for TOPMed, the Consortium on Asthma among African-ancestry Populations in the Americas, and the Atopic Dermatitis Research Network. We also thank all study participants and the authors of the freely available software used in this study. Disclosure of potential conflict of interest: L. A. Beck is a consultant for AbbVie, Allakos, AstraZeneca, Benevolent AIBio, Incyte, Janssen, Leo Pharma, Lilly, Naos Bioderma, Novartis, Pfizer, Principia Biopharma, Rapt Therapeutics, Regeneron, Sanofi/Genzyme, Sanofi-Aventis, UCB, and Vimalan and an investigator for AbbVie, AstraZeneca, Kiniksa, Leo Pharma, Pfizer, Regeneron, and Sanofi, and she has stock in Medtronics, Moderna, and Gilead. R. L. Gallo is a board member of MatriSys Bioscience, has received a consulting fee from Sente, has pending grants through Novan and Regeneron, and has stock in Sente and MatriSys. C. P. Hersh reports a grant from Novartis related to this study and grants from Bayer, Boehringer Ingelheim, and Vertex, as well as personal fees from Takeda outside of this study. D. Y. M. Leung has been a consultant for Sanofi-Genzyme, Genentech, Janssen R&D, AbbVie, Amagma Therapeutics, Boehringer Ingelheim, Leo Pharmaceuticals, and Incyte Pharmaceuticals. E. Guttman-Yassky is an employee of Mount Sinai; she has received research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boerhinger Ingelhiem, Celgene, Dermavant, DS Biopharma, Eli Lilly, Galderma,Glenmark/Ichnos Sciences, Innovaderm, Janssen, Kiniksa, Kyowa Kirin, Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, Inc, Sienna Biopharma, UCB and Union Therapeutics/Antibiotx, and she is a consultant for AbbVie, Aditum Bio, Almirall, Alpine, Amgen, Arena, Asana Biosciences, AstraZeneca, Bluefin Biomedicine, Boerhinger Ingelhiem, Boston Pharmaceuticals, Botanix, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Clinical Outcome Solutions, DBV, Dermavant, Dermira, Douglas Pharmaceutical, DS Biopharma, Eli Lilly, EMD Serono, Evelo Bioscience, Evidera, FIDE, Galderma, GSK, Haus Bioceuticals, Ichnos Sciences, Incyte, Kyowa Kirin, Larrk Bio, Leo Pharma, Medicxi, Medscape, Neuralstem, Noble Insights, Novan, Novartis, Okava Pharmaceuticals, Pandion Therapeutics, Pfizer, Principia Biopharma, RAPT Therapeutics, Realm, Regeneron Pharmaceuticals, Inc, Sanofi, SATO Pharmaceutical, Sienna Biopharma, Seanegy Dermatology, Seelos Therapeutics, Serpin Pharma, Siolta Therapeutics, Sonoma Biotherapeutics, Sun Pharma, Target PharmaSolutions, Union Therapeutics, Vanda Pharmaceuticals, Ventyx Biosciences, Vimalan. A. S. Paller has been a consultant for AbbVie, Arena, Bausch, Bristol Myers Squibb, Dermavant, Eli Lilly, Forte, Leo, Lifemax, Pfizer, Rapt, Regeneron, and Sanofi and an investigator (support to institution) for AbbVie, Eli Lilly, and Regeneron. L. C. Schneider is an investigator for Regneneron and DBV Technologies; a consultant for Amagma, Alladapt, and Ukko; and has grants from Genentech and Pfizer. K. C. Barnes receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program were supported by the National Heart, Lung, and Blood Institute (NHLBI). Genome sequencing for NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish study (phs000956.v4.p1) was performed at Broad Genomics (the genomics platform of the Broad Institute of Harvard and MIT, 3R01HL121007-01S1). Genome sequencing for NHLBI TOPMed: The Genetics and Epidemiology of Asthma in Barbados study (phs001143.v3.p1) was performed at Illumina (3R01HL104608-04S1). We gratefully acknowledge the contributions of Pissamai and Trevor Maul, Paul Levett, Anselm Hennis, P. Michele Lashley, Raana Naidu, Malcolm Howitt, and Timothy Roach, as well as the numerous health care providers and community clinics and coinvestigators who assisted in the phenotyping and collection of DNA samples and the families and patients for generously donating DNA samples to the Barbados Asthma Genetics Study, funding, for which was provided by National Institutes of Health (NIH) (grants R01HL104608, R01HL087699, and HL104608 S1). Genome sequencing for the NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene) project (phs000951.v4.p4) was performed at Broad Genomics (HHSN268201500014C). Genome sequencing for the NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica study (phs000988.v4.p1) was performed at the Northwest Genomics Center (3R37HL066289-13S1). Measurement of IgE levels in the CRA study was supported by R37 HL066289 and P01HL132825. Genome sequencing for the NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study (phs000974.v4.p3) was performed at Broad Genomics (3U54HG003067-12S2). Genome sequencing for the NHLBI TOPMed: Severe Asthma Research Program (phs001446.v1.p1) was performed at New York Genomic Center Genomics (HHSN268201500016C). Core support, including centralized genomic read mapping and genotype calling along with variant quality metrics and filtering, was provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support, including phenotype harmonization, data management, sample-identity quality control, and general program coordination, was provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). The TOPMed component of the Amish Research Program was supported by NIH grants R01 HL121007, U01 HL072515, and R01 AG18728 (e-mail Rhea Cosentino [rcosenti@som.umaryland.edu] for additional input). The COPDGene project was supported by the NHLBI (awards U01 HL089897 and U01 HL089856). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHLBI or the NIH. The COPDGene project is also supported by the Chronic Obstructive Pulmonary Disease Foundation through contributions made to an industry advisory board comprising of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. A full listing of COPDGene investigators can be found at: http://www.copdgene.org/directory . Measurement of IgE levels in COPDGene was supported by R01HL130512 and a grant from Novartis. The Framingham Heart Study acknowledges support from the NHLBI (contracts NO1-HC-25195, HHSN268201500001I, and 75N92019D00031 and grant supplement R01 HL092577-06S1) for this research. We also acknowledge the dedication of the Framingham Heart Study participants, without whom this research would not have been possible. We gratefully acknowledge the studies and participants who provided biologic samples and data for TOPMed, the Consortium on Asthma among African-ancestry Populations in the Americas, and the Atopic Dermatitis Research Network. We also thank all study participants and the authors of the freely available software used in this study. Publisher Copyright: © 2021 The Authors
PY - 2021/12
Y1 - 2021/12
N2 - Background: Total serum IgE (tIgE) is an important intermediate phenotype of allergic disease. Whole genome genetic association studies across ancestries may identify important determinants of IgE. Objective: We aimed to increase understanding of genetic variants affecting tIgE production across the ancestry and allergic disease spectrum by leveraging data from the National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine program; the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA); and the Atopic Dermatitis Research Network (N = 21,901). Methods: We performed genome-wide association within strata of study, disease, and ancestry groups, and we combined results via a meta-regression approach that models heterogeneity attributable to ancestry. We also tested for association between HLA alleles called from whole genome sequence data and tIgE, assessing replication of associations in HLA alleles called from genotype array data. Results: We identified 6 loci at genome-wide significance (P < 5 × 10–9), including 4 loci previously reported as genome-wide significant for tIgE, as well as new regions in chr11q13.5 and chr15q22.2, which were also identified in prior genome-wide association studies of atopic dermatitis and asthma. In the HLA allele association study, HLA-A∗02:01 was associated with decreased tIgE level (Pdiscovery = 2 × 10–4; Preplication = 5 × 10–4; Pdiscovery+replication = 4 × 10–7), and HLA-DQB1∗03:02 was strongly associated with decreased tIgE level in Hispanic/Latino ancestry populations (PHispanic/Latino discovery+replication = 8 × 10–8). Conclusion: We performed the largest genome-wide association study and HLA association study of tIgE focused on ancestrally diverse populations and found several known tIgE and allergic disease loci that are relevant in non-European ancestry populations.
AB - Background: Total serum IgE (tIgE) is an important intermediate phenotype of allergic disease. Whole genome genetic association studies across ancestries may identify important determinants of IgE. Objective: We aimed to increase understanding of genetic variants affecting tIgE production across the ancestry and allergic disease spectrum by leveraging data from the National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine program; the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA); and the Atopic Dermatitis Research Network (N = 21,901). Methods: We performed genome-wide association within strata of study, disease, and ancestry groups, and we combined results via a meta-regression approach that models heterogeneity attributable to ancestry. We also tested for association between HLA alleles called from whole genome sequence data and tIgE, assessing replication of associations in HLA alleles called from genotype array data. Results: We identified 6 loci at genome-wide significance (P < 5 × 10–9), including 4 loci previously reported as genome-wide significant for tIgE, as well as new regions in chr11q13.5 and chr15q22.2, which were also identified in prior genome-wide association studies of atopic dermatitis and asthma. In the HLA allele association study, HLA-A∗02:01 was associated with decreased tIgE level (Pdiscovery = 2 × 10–4; Preplication = 5 × 10–4; Pdiscovery+replication = 4 × 10–7), and HLA-DQB1∗03:02 was strongly associated with decreased tIgE level in Hispanic/Latino ancestry populations (PHispanic/Latino discovery+replication = 8 × 10–8). Conclusion: We performed the largest genome-wide association study and HLA association study of tIgE focused on ancestrally diverse populations and found several known tIgE and allergic disease loci that are relevant in non-European ancestry populations.
KW - Total serum IgE
KW - asthma
KW - atopic dermatitis
KW - genome-wide association study
KW - human leukocyte antigen
KW - multiethnic
UR - http://www.scopus.com/inward/record.url?scp=85117132470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117132470&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.09.011
DO - 10.1016/j.jaci.2021.09.011
M3 - Article
C2 - 34536413
AN - SCOPUS:85117132470
SN - 0091-6749
VL - 148
SP - 1589
EP - 1595
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -